Exosome-Mediated Sleep Deprivation Reversal

1 Kang et al. 2026 β€” HSP70 mRNA-Loaded Exosomes Reverse Sleep Deprivation Brain Damage

Full Citation:: Kang Z, Zhu G, Su C, Zhong X, Lin J, Lin Y. Delivery of HSP70 mRNA via exosomes ameliorates sleep deprivation-induced cognitive impairments in mice. Translational Psychiatry. 2026. https://doi.org/10.1038/s41398-026-04044-z DOI:: 10.1038/s41398-026-04044-z Published:: April 24, 2026 Study Design:: Preclinical mouse model with engineered exosomes Sample Size:: Not specified in abstract (mice) Key Findings:

- Engineered HEK293T cells stably expressing HSP70 mRNA and brain-targeting RVG-Lamp2b fusion protein generated HSP70-ExoRVG exosomes
- HSP70-ExoRVG exosomes efficiently delivered HSP70 mRNA to neural progenitor cells (NPCs), increasing intracellular HSP70 protein
- In vivo systemic administration restored memory performance in sleep-deprived mice
- Treatment reduced hippocampal pro-inflammatory cytokines: TNF-Ξ±, IL-6, IL-1Ξ²
- Treatment increased anti-inflammatory IL-10
- Elevated brain-derived neurotrophic factor (BDNF) and phosphorylated CREB, indicating enhanced neurotrophic signaling
- Effects surpassed those of non-targeted exosomes or empty exosomes
- First demonstration of RVG-modified exosomes successfully delivering mRNA (rather than siRNA or miRNA) for treating sleep deprivation-induced deficits
- HSP70-ExoRVG offers promising noninvasive therapeutic strategy for sleep-related neurodegenerative conditions

Relevance: First study to demonstrate engineered exosomes can deliver therapeutic mRNA across the BBB to reverse cognitive and inflammatory consequences of sleep deprivation. The RVG targeting strategy enables brain-specific delivery without invasive procedures. Reduction of pro-inflammatory cytokines (TNF-Ξ±, IL-6, IL-1Ξ²) and enhancement of neurotrophic signaling (BDNF, pCREB) address core pathophysiological processes that may overlap with ME/CFS: sleep disturbance, cognitive impairment, and neuroinflammation. Provides proof-of-concept for exosome-based mRNA delivery as a potential ME/CFS therapeutic approach, though direct ME/CFS data is absent.

Certainty Assessment:

- *Quality:* Medium (published in *Translational Psychiatry* [Nature portfolio], peer-reviewed)
- *Sample:* Preclinical mice model; sample size not specified
- *Replication:* None yet (published April 2026)
- *Methodology:* Engineered exosomes characterized via TEM, NTA, Western blot; behavioral tests; molecular analyses of inflammatory and neurotrophic markers β€” standard preclinical methods
- *Limitations:* Single preclinical study; animal model only; no replication; no direct ME/CFS relevance; chronic ME/CFS pathology differs from acute sleep deprivation model; safety and scalability for clinical translation unknown; long-term effects of repeated exosome administration not studied

2 Ramos-Zald{'i}var et al. 2022 β€” Extracellular Vesicles BBB Crossing Mechanisms

Full Citation:: Ramos-Zald{'i}var HM, Polakovicova I, Salas-Huenuleo E, Corval{'a}n AH, Kogan MJ, Yefi CP, Andia ME. Extracellular vesicles through the blood–brain barrier: a review. Fluids and Barriers of the CNS. 2022;19(1):60. DOI:: 10.1186/s12987-022-00359-3 PMID:: 35853456 PMCID:: PMC9331269 Published:: July 25, 2022 Study Design:: Systematic review Sample Size:: N/A (review paper with 268 citations) Key Findings:

- Bidirectional EV transport across BBB remains poorly understood
- Most evidence from in vitro models: monolayer transwell assays, microfluidic organ-on-a-chip techniques
- No direct transcytosis visualization through BBB in mammals in vivo
- Evidence comes from in vivo experiments in zebrafish
- Multiple proposed EV crossing mechanisms identified: macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated endocytosis, adsorptive-mediated endocytosis
- Inflammation enhances EV permeability: TNF-Ξ± and LPS treatment increases EV crossing in transwell models
- EVs can cross intact BBB or disrupt BBB integrity depending on EV origin and experimental conditions
- BBB models vary in complexity: monolayer (most common), bilayer (endothelium + pericytes), tri-layer (endothelium + pericytes + astrocytes)
- EVs from breast cancer cells show internalization in endothelial cells but limited crossing beyond endothelium in multi-layer models
- EVs from HEK 293T cells and erythrocytes cross BBB monolayers only when inflammation is simulated

Relevance: Systematic review of BBB crossing mechanisms provides foundational understanding for exosome-based drug delivery to brain. Identifies multiple active transport pathways (endocytosis, transcytosis) rather than passive diffusion, suggesting engineering strategies can enhance BBB crossing. Inflammation-enhanced permeability may be relevant to ME/CFS if neuroinflammation or systemic inflammation increases BBB EV transport, potentially facilitating therapeutic delivery but also permitting pathological EV communication. Highlights methodological limitations: most data from in vitro models, limited in vivo mammalian evidence, zebrafish data may not translate to mammals. Critical for evaluating translational potential of exosome therapies for ME/CFS CNS targets.

Certainty Assessment:

- *Quality:* High (systematic review in *Fluids and Barriers of the CNS*, BMC journal, 268 citations)
- *Sample:* N/A (review synthesizes multiple studies)
- *Replication:* N/A (review paper)
- *Limitations:* Limited primary data on mammalian in vivo BBB transcytosis; focuses on EV transport mechanisms generally rather than mRNA cargo delivery specifically; heterogeneity across studies in EV origin, isolation methods, and BBB models complicates generalizability

3 Sanadgol et al. 2025 β€” Exosomes as Brain-Targeted NA-BT Nanocarriers

Full Citation:: Sanadgol N, Abedi M, Hashemzaei M, Kamran Z, Khalseh R, Beyer C, Voelz C. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. Journal of Nanobiotechnology. 2025;23:453. DOI:: 10.1186/s12951-025-03528-2 PMID:: 40533746 PMCID:: PMC12178025 Published:: June 18, 2025 Study Design:: Comprehensive review Sample Size:: N/A (review paper) Key Findings:

- Comprehensive overview of nucleic acid-based therapies (NA-BTs) for CNS disorders
- NA-BT types covered: siRNAs, miRNAs, antisense oligonucleotides (ASOs), mRNAs, aptamers, peptide nucleic acids (PNAs), DNAs, DNAzymes, CRISPR/Cas systems
- BBB structure and function overview: endothelial cells, pericytes, astrocytes, neurons (neurovascular unit)
- Exosome advantages: biocompatibility, capacity to cross biological barriers, protection of nucleic acid cargo, lower immunogenicity than viral vectors
- Exosome engineering strategies for brain targeting: surface modification (e.g., RVG peptide), cargo loading (electroporation, incubation, transfection), donor cell engineering
- Comparison with conventional nanocarriers: exosomes show advantages over lipid nanoparticles (LNPs) for brain delivery but face scalability challenges
- Comparison with cell-based therapies: exosomes avoid cell transplantation risks but have limited cargo capacity
- Methodological limitations identified: cargo variability between batches, heterogeneity in isolation techniques, lack of standardization, safety concerns (off-target effects, immunogenicity)
- Clinical translation challenges: manufacturing scalability, quality control, regulatory pathways
- Applications discussed for neurodegenerative diseases (Alzheimer's, Parkinson's), stroke, traumatic brain injury, multiple sclerosis, brain tumors

Relevance: Most comprehensive recent review on exosomes as nucleic acid delivery vehicles to brain. Establishes the conceptual and technical framework for understanding Kang 2026’s HSP70 mRNA delivery approach. Provides mechanistic rationale for why exosomes may be superior to LNPs for CNS delivery: natural BBB-crossing capability, lower immunogenicity, biocompatibility. Identifies key challenges that directly inform translational potential for ME/CFS: cargo variability (may affect dosing consistency), scalability (may limit accessibility), safety (concern for ME/CFS patients with immune dysregulation). Comparison with cell-based therapies and LNPs helps contextualize exosomes within broader therapeutic landscape. Discussion of neurodegenerative disease applications provides cross-disease parallels, though ME/CFS-specific data absent.

Certainty Assessment:

- *Quality:* High (comprehensive review in *Journal of Nanobiotechnology*, recent 2025 publication, extensive referencing)
- *Sample:* N/A (review paper)
- *Replication:* N/A (review paper)
- *Limitations:* Review format synthesizes existing literature rather than providing primary data; limited discussion of negative results or failed clinical trials; ME/CFS not specifically addressed; therapeutic optimism not balanced with safety data from human trials